BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38512117)

  • 1. A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.
    Agarwal N; Castellano D; Alonso-Gordoa T; Arranz Arija JA; Colomba E; Gravis G; Mourey L; Oudard S; Fléchon A; González M; Rey PM; Schweizer MT; Gallardo E; Johnston E; Balar A; Haddad N; Appiah AK; Nacerddine K; Piulats JM
    Clin Cancer Res; 2024 Jun; 30(11):2377-2383. PubMed ID: 38512117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR
    Dickler MN; Tolaney SM; Rugo HS; Cortés J; Diéras V; Patt D; Wildiers H; Hudis CA; O'Shaughnessy J; Zamora E; Yardley DA; Frenzel M; Koustenis A; Baselga J
    Clin Cancer Res; 2017 Sep; 23(17):5218-5224. PubMed ID: 28533223
    [No Abstract]   [Full Text] [Related]  

  • 3. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer.
    Tolaney SM; Sahebjam S; Le Rhun E; Bachelot T; Kabos P; Awada A; Yardley D; Chan A; Conte P; Diéras V; Lin NU; Bear M; Chapman SC; Yang Z; Chen Y; Anders CK
    Clin Cancer Res; 2020 Oct; 26(20):5310-5319. PubMed ID: 32694159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
    Choi YJ; Kim HS; Park SH; Kim BS; Kim KH; Lee HJ; Song HS; Shin DY; Lee HY; Kim HG; Lee KH; Lee JL; Park KH
    Cancer Res Treat; 2018 Oct; 50(4):1252-1259. PubMed ID: 29334610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
    Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
    Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
    Hamilton E; Cortes J; Ozyilkan O; Chen SC; Petrakova K; Manikhas A; Jerusalem G; Hegg R; Huober J; Chapman SC; Lu Y; Hardebeck MC; Bear MM; Johnston EL; Martin M
    Clin Breast Cancer; 2021 Jun; 21(3):181-190.e2. PubMed ID: 33148479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
    Armstrong AJ; Halabi S; Healy P; Alumkal JJ; Winters C; Kephart J; Bitting RL; Hobbs C; Soleau CF; Beer TM; Slottke R; Mundy K; Yu EY; George DJ
    Eur J Cancer; 2017 Aug; 81():228-236. PubMed ID: 28502694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
    Patnaik A; Rosen LS; Tolaney SM; Tolcher AW; Goldman JW; Gandhi L; Papadopoulos KP; Beeram M; Rasco DW; Hilton JF; Nasir A; Beckmann RP; Schade AE; Fulford AD; Nguyen TS; Martinez R; Kulanthaivel P; Li LQ; Frenzel M; Cronier DM; Chan EM; Flaherty KT; Wen PY; Shapiro GI
    Cancer Discov; 2016 Jul; 6(7):740-53. PubMed ID: 27217383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
    Hussain M; Carducci MA; Slovin S; Cetnar J; Qian J; McKeegan EM; Refici-Buhr M; Chyla B; Shepherd SP; Giranda VL; Alumkal JJ
    Invest New Drugs; 2014 Oct; 32(5):904-12. PubMed ID: 24764124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abemaciclib: The Newest CDK4/6 Inhibitor for the Treatment of Breast Cancer.
    Palumbo A; Lau G; Saraceni M
    Ann Pharmacother; 2019 Feb; 53(2):178-185. PubMed ID: 30099886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin-Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With Metastatic Breast Cancer.
    Ratosa I; Orazem M; Scoccimarro E; Steinacher M; Dominici L; Aquilano M; Cerbai C; Desideri I; Ribnikar D; Marinko T; Livi L; Meattini I
    Clin Breast Cancer; 2020 Dec; 20(6):495-502. PubMed ID: 32622736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.
    Corona SP; Generali D
    Drug Des Devel Ther; 2018; 12():321-330. PubMed ID: 29497278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
    J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
    Fong L; Morris MJ; Sartor O; Higano CS; Pagliaro L; Alva A; Appleman LJ; Tan W; Vaishampayan U; Porcu R; Tayama D; Kadel EE; Yuen KC; Datye A; Armstrong AJ; Petrylak DP
    Clin Cancer Res; 2021 Sep; 27(17):4746-4756. PubMed ID: 34108181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
    Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
    Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.